Prkc-ζ expression promotes the aggressive phenotype of human prostate cancer cells and is a novel target for therapeutic intervention Academic Article uri icon


MeSH Major

  • Prostatic Neoplasms


  • We show protein kinase C-zeta (PKC-ζ) to be a novel predictive biomarker for survival from prostate cancer (P < 0.001). We also confirm that transcription of the PRKC-ζ gene is crucial to the malignant phenotype of human prostate cancer. Following siRNA silencing of PRKC-ζ in PC3-M prostate cancer cells, stable transfectant cell line si-PRKC-ζ-PC3-M(T1-6) is phenotypically nonmalignant in vitro and in vivo. Genome-wide expression analysis identified 373 genes to be differentially expressed in the knockdown cells and 4 key gene networks to be significantly perturbed during phenotype modulation. Functional interconnection between some of the modulated genes is revealed, although these may be within different regulatory pathways, emphasizing the complexity of their mutual interdependence. Genes with altered expression following PRKC-ζ knockdown include HSPB1, RAD51, and ID1 that we have previously described to be critical in prostatic malignancy. Because expression of PRKC-ζ is functionally involved in promoting the malignant phenotype, we propose PKC-ζ as a novel and biologically relevant target for therapeutic intervention in prostate cancer.

publication date

  • December 2010



  • Academic Article



  • eng

PubMed Central ID

  • PMC3092210

Digital Object Identifier (DOI)

  • 10.1177/1947601910376079

PubMed ID

  • 21779455

Additional Document Info

start page

  • 444

end page

  • 64


  • 1


  • 5